
Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.
Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.
In a recent study, vaccination administered during pregnancy was effective against severe lower respiratory tract illness associated with respiratory syncytial virus in infants.
Published: August 11th 2025 | Updated: August 13th 2025
Published: July 22nd 2025 | Updated: July 23rd 2025
Published: May 30th 2024 | Updated: January 7th 2025
Published: May 3rd 2024 | Updated: January 6th 2025
Published: March 5th 2024 | Updated: August 6th 2024
Published: July 15th 2025 | Updated: